Core Viewpoint - Alkermes (ALKS) has shown a significant price increase of 12.1% over the past four weeks, with a mean price target of $41.76 indicating a potential upside of 34.8% from the current price of $30.98 [1] Price Targets and Analyst Consensus - The average price target consists of 17 estimates ranging from a low of $30.00 to a high of $54.00, with a standard deviation of $6.16, indicating variability among analysts [2] - The lowest estimate suggests a decline of 3.2%, while the highest indicates a potential upside of 74.3% [2] - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Upside Potential - Analysts have shown increasing optimism about ALKS's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 4.1% over the past month, with no negative revisions [12] - ALKS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research indicates that they rarely predict actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]

Group 1 - Alkermes (ALKS) is currently outperforming its peers in the Medical sector with a year-to-date return of 7.7%, compared to the sector average of 1.7% [4] - The Zacks Rank for Alkermes is 2 (Buy), indicating a positive outlook based on earnings estimates and revisions, with a 15.4% increase in the consensus estimate for full-year earnings over the past 90 days [3] - Alkermes is part of the Medical - Biomedical and Genetics industry, which has seen a year-to-date gain of 10.6%, indicating that ALKS is slightly underperforming its industry [6] Group 2 - The Medical group consists of 956 companies and is currently ranked 4 in the Zacks Sector Rank, which evaluates 16 different sector groups [2] - Another stock in the Medical sector, Brainsway Ltd. Sponsored ADR (BWAY), has significantly outperformed with a year-to-date increase of 68.4% and also holds a Zacks Rank of 2 (Buy) [4][5] - The Medical - Products industry, which includes Brainsway, has a lower ranking at 95 and has gained 5.3% since the beginning of the year [7]

Core Insights - Alkermes (ALKS) is currently rated with a Zacks Rank 2 (Buy) and has a Value grade of A, indicating strong potential for value investors [4][3] - The stock's Forward P/E ratio is 15.85, significantly lower than the industry average of 39.01, suggesting it may be undervalued [4] - ALKS has a PEG ratio of 1.29, compared to the industry's average of 2.83, indicating favorable earnings growth relative to its price [5] - The P/B ratio for ALKS is 2.82, which is lower than the industry average of 3.42, further supporting its value proposition [6] - The P/S ratio stands at 3.4, compared to the industry's average of 6.84, reinforcing the notion that ALKS is undervalued [7] - Overall, the combination of these metrics suggests that ALKS is an impressive value stock with a strong earnings outlook [8]

Core Points - Alkermes plc will host a conference call and webcast presentation on October 28, 2025, at 8:00 a.m. ET to discuss its third quarter financial results [1] - The conference call can be accessed via specific phone numbers for U.S. and international callers, and a replay will be available on the company's website [2] - Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience, with a portfolio addressing alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [2] - The company has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia [2] - Alkermes is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [2] Additional Information - Joshua Reed has been appointed as Chief Financial Officer, effective September 15, 2025 [3] - Alkermes has announced the launch of its 8th Annual Alkermes Pathways Research Awards program [4]

Core Insights - Alkermes plc is a biopharmaceutical company focused on innovative medicines for central nervous system disorders and oncology, with a strong product pipeline and strategic initiatives for future growth [1] - The company operates in a competitive industry alongside major players like Biogen and Amgen, but its unique focus and robust financial health differentiate it [1] Recent Performance - Alkermes has shown a notable monthly gain of approximately 8.89%, indicating a strong upward trend [2][6] - However, the stock experienced a slight decline of about 2.36% in the last 10 days, which may present a strategic entry point for investors [2][6] Growth Potential - The stock has significant growth potential, with an estimated increase of approximately 44.75%, suggesting that it is currently undervalued [3][6] - The target price for Alkermes is set at $43.80, aligning with its growth potential and providing a clear upside for investors [3] Financial Health - Alkermes has a perfect Piotroski Score of 9, indicating robust financial health, efficient operations, and potential for future growth [4] - A score of 9 reflects the company's solid financial foundation, making it an attractive investment option [4] Investment Opportunity - Overall, Alkermes presents a compelling investment opportunity due to its recent stock price dip, strong financial metrics, and growth potential [5] - The significant upside associated with the target price of $43.80 makes it an appealing option for investors [5]

Upgrades Summary - Rothschild & Co Redburn upgraded Kenvue (KVUE) to Buy from Neutral with a price target of $22, down from $22.50, citing a more measured response from the Health and Human Services department regarding Tylenol usage concerns [2] - Rosenblatt upgraded Ciena (CIEN) to Buy from Neutral with a price target of $175, up from $127.50, following an innovation day that highlighted opportunities to network multiple AI data centers [2] - Citi upgraded Riot Platforms (RIOT) to Buy from Neutral with a price target of $24, up from $13.75, due to the company's transition to AI and high-performance computing [2] - JPMorgan also upgraded Riot Platforms to Overweight from Neutral with a price target of $19, up from $15 [2] - Goldman Sachs upgraded Ionis Pharmaceuticals (IONS) to Neutral from Sell with a price target of $65, up from $45, noting the company's transition to a commercial growth story [2] - RBC Capital upgraded Alkermes (ALKS) to Outperform from Sector Perform with a price target of $44, up from $42, based on positive analysis of potential narcolepsy type 2 treatment effects for alixorexton [2]

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Considering buying CIEN stock? Here’s what analysts think: Read This Next: Photo via ShutterstockLoading...Loading... ...

Group 1 - Alkermes is recognized as one of the best beginner stocks to buy, with a 'Neutral' rating and a $46 price target from HC Wainwright following positive results from the Vibrance-1 phase 2 study [1][2] - The Vibrance-1 study results indicate that Alixorexton is the first orexin 2 receptor agonist to show a clinically meaningful and statistically significant impact on wakefulness, cognition, and fatigue [2][3] - Improvements in patient-reported outcomes related to fatigue and cognitive function suggest that Alixorexton may provide significant relief for patients suffering from narcolepsy and idiopathic hypersomnia [3] Group 2 - Alkermes is a global biopharmaceutical company focused on developing and commercializing treatments for complex psychiatric and neurological disorders, including addiction, schizophrenia, and bipolar disorder [4] - The company has a diverse portfolio of marketed products and a pipeline of investigational drug candidates, emphasizing its commitment to neuroscience innovation [4]

Core Insights - Alkermes plc is advancing in the development of treatments for neurological and psychiatric disorders, focusing on conditions like alcohol and opioid dependence, schizophrenia, and bipolar I disorder, while also exploring narcolepsy and idiopathic hypersomnia [1] - The appointment of Joshua Reed as Chief Financial Officer is expected to enhance Alkermes' commercial performance and pipeline progression, leveraging his extensive experience in the biotechnology and pharmaceutical sectors [2] - Alkermes demonstrates a robust market position with a P/E ratio of 12.77, a price-to-sales ratio of 2.96, and an enterprise value to sales ratio of 2.66, indicating favorable market valuation [3] Financial Health - The company has a low debt-to-equity ratio of 0.045, reflecting prudent debt management, and a strong current ratio of 3.23, indicating solid short-term financial health and liquidity [4] - Analysts have set optimistic price targets for Alkermes, projecting potential price increases of 54.4% and 65.68% from the current stock price [4]

Core Insights - Alkermes plc has appointed Joshua Reed as Chief Financial Officer (CFO), effective September 15, 2025, reporting to CEO Richard Pops [1] - Mr. Reed has over 30 years of financial leadership experience, particularly in the biotechnology and pharmaceutical sectors, previously serving as CFO at Omega Therapeutics and Aldeyra Therapeutics [2] - The CEO expressed confidence in Mr. Reed's financial expertise and strategic insight, highlighting the importance of his role in driving performance and shareholder value [4] Company Overview - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience, with a portfolio addressing alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [4] - The company has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia [4] - Alkermes is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [4]